Trevena Reports Second Quarter 2022 Results and Provides Business Update
Trevena, Inc. (Nasdaq: TRVN) announced its second-quarter 2022 results, reporting a net loss of $15 million, with a cash balance of $49.5 million sufficient to fund operations into mid-2023. The company continues positive engagement in launching OLINVYK, having signed a multi-year agreement with Vizient for broader access. Recent data showed OLINVYK significantly reduces neurocognitive impairment compared to IV morphine. Additionally, the Phase 1 study of TRV045 for diabetic neuropathic pain is on track, with completion expected in 2H 2022.
- OLINVYK demonstrated statistically significant improvement in cognitive function over IV morphine.
- Strategic partnership with Vizient enhances access to OLINVYK, benefiting hospital patients.
- Phase 1 study of TRV045 remains on track with full enrollment in critical study segments.
- Positive preclinical data for TRV045 indicate potential efficacy in epilepsy treatment.
- Net loss of $15 million for Q2 2022, same per share loss as Q2 2021.
- Dependence on cash balance of $49.5 million limits financial runway to mid-2023.
OLINVYK post-approval strategy advances with positive topline cognitive function data and continued enrollment in VOLITION clinical outcomes study
Phase 1 study for TRV045, a novel S1P receptor modulator, on track for year-end data readout; single ascending dose and food effect study segments fully enrolled
TRV045 demonstrated potential antiepileptic effect in multiple preclinical models
Cash balance of
Company to host conference call today, August 11, 2022 at 8:00 a.m. ET
CHESTERBROOK, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the second quarter ended June 30, 2022 and provided an overview of its recent operational highlights.
“We recognize the macro headwinds our hospital customers are facing and have made disciplined choices around our business to efficiently commercialize OLINVYK with our refocused sales and medical affairs team. The recently signed Vizient contract will also help us reach important hospital decision-makers and further supports OLINVYK’s potential clinical and health economic benefits,” said Carrie Bourdow, President and CEO of Trevena. “We’re also responding to our customers during this time by continuing to provide new OLINVYK data versus IV morphine in important areas such as respiratory and cognitive function adverse events where there is a need to improve acute pain patients’ outcomes. Lastly, I’m pleased that we’ve advanced our novel S1P receptor modulator, TRV045, towards Phase 1 completion and I’m excited about the potential opportunity in both diabetic neuropathic pain and epilepsy.”
Second Quarter 2022 and Recent Corporate Highlights
OLINVYK (oliceridine) injection Milestones
- Continued progress on launch execution. We continue to see hospital utilization of OLINVYK and the addition of new accounts in the second quarter. In July, Trevena entered into a multi-year agreement with Vizient, Inc., a leading hospital performance improvement company, which will allow for broad OLINVYK access for enhanced savings for member hospitals. Vizient serves more than half of U.S. hospitals in its customer network that includes
97% of the U.S. academic medical centers,50% of acute care hospitals and20% of the ambulatory surgical centers. Trevena will work with Vizient to educate its members on the clinical and health economic benefits of OLINVYK as an alternative to IV morphine. - Announced results from cognitive function study that demonstrated statistically significant reduced impact on neurocognitive functioning vs IV morphine on primary endpoint. OLINVYK was studied in a randomized, double-blind placebo-controlled dose-ranging design, in collaboration with the Netherlands-based Center for Human Drug Research. Subjects received single intravenous doses of OLINVYK 1 mg and 3 mg, or morphine 5 mg and 10 mg, or placebo, using a partial-block crossover design. On the primary endpoint, OLINVYK showed a statistically significant reduction in sedation versus IV morphine, measured by saccadic eye movement peak velocity, a sensitive laboratory measure of sedating action of medications. On several of the prespecified secondary outcome measures, OLINVYK showed a statistically significant difference or trend compared to IV morphine, despite the relatively small sample size, across a range of neurocognitive measures and motor performance. The Company expects to submit these results at scientific meetings in the coming months.
“I believe these data are a very important addition to the scientific evidence on OLINVYK and should be of great interest to practicing clinicians”, said Ashish Khanna, MD, Associate Professor of Anesthesiology and Vice Chair of Research, at Atrium Health Wake Forest Baptist Medical Center, “Any reduction in neurocognitive impairment has potentially significant implications for postoperative recovery, where getting the patient out of bed and moving as soon as possible is a critical component of modern multimodal approaches to post-surgical care. If these study outcomes translate into clinical practice, they may potentially result in meaningful reductions in length of stay, improved ambulation, and avoidance of falls.”
- VOLITION Clinical Outcomes Study on track to conclude enrollment later this year. The Company expects enrollment in the VOLITION study to conclude later this year. The VOLITION study is being led by clinical outcomes research experts from the Cleveland Clinic and the Wake Forest Baptist Health Medical Center. The study is assessing the potential impact of OLINVYK on respiratory, gastrointestinal (GI) and cognitive function outcomes in the postoperative setting.
Pipeline Updates
- Phase 1 study of TRV045, in development for diabetic neuropathic pain, remains on track for completion in 2H 2022. Phase 1 study has continued to progress with full enrollment in the single ascending dose and food effect segments of the study. The Company expects to complete the remaining multiple ascending dose portion later this year.
- NIH epilepsy program studying TRV045 advances with positive preclinical data. Data showed evidence of acute prevention of seizures and evidence of efficacy in two different complex models of refractory epilepsy. The Company plans to prepare the data to move forward into clinical development for a potential epilepsy indication.
Financial Results for Second Quarter 2022
For the second quarter of 2022, the Company reported a net loss attributable to common stockholders of
Cash and cash equivalents were
Conference Call and Webcast Information
The Company will host a conference call and webcast with the investment community on August 11, 2022, at 8:00 a.m. Eastern Time featuring remarks by Carrie Bourdow, President and Chief Executive Officer, Patricia Drake, Chief Commercial Officer, Mark Demitrack, M.D., Senior Vice President and Chief Medical Officer, and Barry Shin, Chief Financial Officer.
| Title: | Trevena Second Quarter 2022 Financial Results Conference Call & Webcast | ||
| Date: | Thursday, August 11, 2022 | ||
| Time: | 8:00 a.m. ET | ||
| Conference Call Details: | Toll-Free: 1-877-704-4453 International: 1-201-389-0920 Conference ID: 13730949 | ||
| The conference call will be webcast live from the Company’s website and will be available via the following links: | |||
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1557037&tp_key=b050aa54b6 | ||
| The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website. | |||
About OLINVYK® (oliceridine) injection
OLINVYK is a new chemical entity approved by the FDA in August 2020. OLINVYK contains oliceridine, an opioid, which is a Schedule II controlled substance with a high potential for abuse similar to other opioids. It is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. OLINVYK is available in 1 mg/1 mL and 2 mg/2 mL single-dose vials, and a 30 mg/30 mL single-patient-use vial for patient-controlled analgesia (PCA). Approved PCA doses are 0.35 mg and 0.5 mg and doses greater than 3 mg should not be administered. The cumulative daily dose should not exceed 27 mg. Please see Important Safety Information, including the BOXED WARNING, and full prescribing information at www.OLINVYK.com.
IMPORTANT SAFETY INFORMATION
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CENTRAL NERVOUS SYSTEM (CNS) DEPRESSANTS
ADDICTION, ABUSE, AND MISUSE – OLINVYK exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk before prescribing OLINVYK, and monitor all patients regularly for the development of behaviors or conditions.
LIFE-THREATENING RESPIRATORY DEPRESSION – Serious, life-threatening, or fatal respiratory depression may occur with use of OLINVYK. Monitor for respiratory depression, especially during initiation of OLINVYK or following a dose increase.
NEONATAL OPIOID WITHDRAWAL SYNDROME – Prolonged use of OLINVYK during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.
RISK FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS – Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation.
INDICATIONS AND USAGE
OLINVYK is an opioid agonist indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.
Limitations of Use
Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve OLINVYK for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:
- Have not been tolerated, or are not expected to be tolerated
- Have not provided adequate analgesia, or are not expected to provide adequate analgesia.
The cumulative total daily dose should not exceed 27 mg, as total daily doses greater than 27 mg may increase the risk for QTc interval prolongation.
CONTRAINDICATIONS
OLINVYK is contraindicated in patients with:
- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Known hypersensitivity to oliceridine (e.g., anaphylaxis)
WARNINGS AND PRECAUTIONS
- OLINVYK contains oliceridine, a Schedule II controlled substance, that exposes users to the risks of addiction, abuse, and misuse. Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed OLINVYK. Assess risk, counsel, and monitor all patients receiving opioids.
- Serious, life-threatening respiratory depression has been reported with the use of opioids, even when used as recommended, especially in patients with chronic pulmonary disease, or in elderly, cachectic and debilitated patients. The risk is greatest during initiation of OLINVYK therapy, following a dose increase, or when used with other drugs that depress respiration. Proper dosing of OLINVYK is essential, especially when converting patients from another opioid product to avoid overdose. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient’s clinical status.
- Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia with risk increasing in a dose-dependent fashion. In patients who present with CSA, consider decreasing the dose of opioid using best practices for opioid taper.
- Prolonged use of opioids during pregnancy can result in withdrawal in the neonate that may be life-threatening. Observe newborns for signs of neonatal opioid withdrawal syndrome and manage accordingly. Advise pregnant women using OLINVYK for a prolonged period of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.
- Profound sedation, respiratory depression, coma, and death may result from the concomitant use of OLINVYK with benzodiazepines or other CNS depressants (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, or alcohol). Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate, prescribe the lowest effective dose, and minimize the duration.
- OLINVYK was shown to have mild QTc interval prolongation in thorough QT studies where patients were dosed up to 27 mg. Total cumulative daily doses exceeding 27 mg per day were not studied and may increase the risk for QTc interval prolongation. Therefore, the cumulative total daily dose of OLINVYK should not exceed 27 mg.
- Increased plasma concentrations of OLINVYK may occur in patients with decreased Cytochrome P450 (CYP) 2D6 function or normal metabolizers taking moderate or strong CYP2D6 inhibitors; also in patients taking a moderate or strong CYP3A4 inhibitor, in patients with decreased CYP2D6 function who are also receiving a moderate or strong CYP3A4 inhibitor, or with discontinuation of a CYP3A4 inducer. These patients may require less frequent dosing and should be closely monitored for respiratory depression and sedation at frequent intervals. Concomitant use of OLINVYK with CYP3A4 inducers or discontinuation of a moderate or strong CYP3A4 inhibitor can lower the expected concentration, which may decrease efficacy, and may require supplemental doses.
- Cases of adrenal insufficiency have been reported with opioid use (usually greater than one month). Presentation and symptoms may be nonspecific and include nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. If confirmed, treat with physiologic replacement doses of corticosteroids and wean patient from the opioid.
- OLINVYK may cause severe hypotension, including orthostatic hypotension and syncope in ambulatory patients. There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics). Monitor these patients for signs of hypotension. In patients with circulatory shock, avoid the use of OLINVYK as it may cause vasodilation that can further reduce cardiac output and blood pressure.
- Avoid the use of OLINVYK in patients with impaired consciousness or coma. OLINVYK should be used with caution in patients who may be susceptible to the intracranial effects of CO2 retention, such as those with evidence of increased intracranial pressure or brain tumors, as a reduction in respiratory drive and the resultant CO2 retention can further increase intracranial pressure. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy.
- As with all opioids, OLINVYK may cause spasm of the sphincter of Oddi, and may cause increases in serum amylase. Monitor patients with biliary tract disease, including acute pancreatitis, for worsening symptoms.
- OLINVYK may increase the frequency of seizures in patients with seizure disorders and may increase the risk of seizures in vulnerable patients. Monitor patients with a history of seizure disorders for worsened seizure control.
- Do not abruptly discontinue OLINVYK in a patient physically dependent on opioids. Gradually taper the dosage to avoid a withdrawal syndrome and return of pain. Avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving OLINVYK, as they may reduce the analgesic effect and/or precipitate withdrawal symptoms.
- OLINVYK may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery.
- Although self-administration of opioids by patient-controlled analgesia (PCA) may allow each patient to individually titrate to an acceptable level of analgesia, PCA administration has resulted in adverse outcomes and episodes of respiratory depression. Health care providers and family members monitoring patients receiving PCA analgesia should be instructed in the need for appropriate monitoring for excessive sedation, respiratory depression, or other adverse effects of opioid medications.
ADVERSE REACTIONS
Adverse reactions are described in greater detail in the Prescribing Information.
The most common (incidence ≥
MEDICAL INFORMATION
For medical inquiries or to report an adverse event, other safety-related information or product complaints for a company product, please contact the Trevena Medical Information Contact Center at 1-844-465-4686 or email MedInfo@Trevena.com.
You are encouraged to report suspected adverse events of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see Full Prescribing Information, including Boxed Warning.
About TRV045
TRV045 is a novel, selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. Through a collaboration with the National Institutes of Health, Trevena is also exploring TRV045 as a potential treatment for epilepsy.
S1P receptors are located throughout the body, including the central nervous system, where they are believed to play a role in modulating neurotransmission and membrane excitability.
Trevena's discovery efforts have identified a family of compounds that are highly selective for the S1P1 receptor. TRV045 reversed thermal hyperalgesia, a measure of neuropathic pain, in nonclinical models of diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy. TRV045 was not associated with lymphopenia and produced no changes in blood pressure, heart rate, or respiratory function at or above pharmacologically active doses in nonclinical studies.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK® (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s novel pipeline is based on Nobel Prize winning research and includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder.
For more information, please visit www.Trevena.com
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development and trials of its therapeutic candidates, plans for potential future product candidates and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the status, timing, costs, results and interpretation of the Company’s clinical trials or any future trials of any of the Company’s investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company’s assessment of discussions with FDA; available funding; uncertainties related to the Company’s intellectual property; uncertainties related to the ongoing COVID-19 pandemic, other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates and approved product; and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.
For more information, please contact:
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
(617) 430-7576
PR & Media Contact:
Sasha Bennett
Associate Vice President
Clyde Group
Sasha.Bennett@clydegroup.com
(239) 248-3409
Company Contact:
Bob Yoder
SVP and Chief Business Officer
Trevena, Inc.
(610) 354-8840
| TREVENA, INC. | |||||||||||||||||
| Condensed Statements of Operations | |||||||||||||||||
| (Unaudited, in thousands except share and per share data) | |||||||||||||||||
| Three Months Ended Jun 30, | Six Months Ended Jun 30, | ||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | ||||||||||||||
| Product revenue | $ | - | $ | 178 | $ | - | $ | 387 | |||||||||
| License revenue | - | - | 20 | - | |||||||||||||
| Total revenue | - | 178 | 20 | 387 | |||||||||||||
| Operating expenses: | |||||||||||||||||
| Cost of goods sold | 216 | 258 | 423 | 421 | |||||||||||||
| Selling, general and administrative | 10,306 | 10,545 | 21,320 | 17,913 | |||||||||||||
| Research and development | 4,291 | 3,449 | 9,550 | 6,085 | |||||||||||||
| Total operating expenses | 14,813 | 14,252 | 31,293 | 24,419 | |||||||||||||
| Loss from operations | (14,813 | ) | (14,074 | ) | (31,273 | ) | (24,032 | ) | |||||||||
| Other income | (168 | ) | 52 | (97 | ) | 168 | |||||||||||
| Net loss | $ | (14,981 | ) | $ | (14,022 | ) | $ | (31,370 | ) | $ | (23,864 | ) | |||||
| Per share information: | |||||||||||||||||
| Net loss per share of common stock, basic and diluted | ($ | 0.09 | ) | ($ | 0.09 | ) | ($ | 0.19 | ) | ($ | 0.15 | ) | |||||
| Weighted average shares outstanding, basic and diluted | 165,527,087 | 163,370,485 | 165,523,567 | 161,936,680 | |||||||||||||
| TREVENA, INC. | ||||||||||
| Condensed Balance Sheets | ||||||||||
| (Unaudited, in thousands) | ||||||||||
| June 30, 2022 | December 31, 2021 | |||||||||
| Assets | ||||||||||
| Current assets: | ||||||||||
| Cash and cash equivalents | $ | 19,589 | $ | 66,923 | ||||||
| Marketable securities | 29,934 | - | ||||||||
| Inventories | 2,990 | 2,352 | ||||||||
| Prepaid expenses and other current assets | 3,270 | 1,448 | ||||||||
| Total current assets | 55,783 | 70,723 | ||||||||
| Restricted cash | 2,911 | 1,311 | ||||||||
| Property and equipment, net | 1,631 | 1,841 | ||||||||
| Right-of-use lease assets | 4,474 | 4,706 | ||||||||
| Other assets | 3 | 1,543 | ||||||||
| Total assets | $ | 64,802 | $ | 80,124 | ||||||
| Liabilities and stockholders’ equity | ||||||||||
| Current liabilities: | ||||||||||
| Accounts payable, net | $ | 2,719 | $ | 4,547 | ||||||
| Accrued expenses and other current liabilities | 5,951 | 3,847 | ||||||||
| Current portion of lease liabilities | 839 | 792 | ||||||||
| Total current liabilities | 9,509 | 9,186 | ||||||||
| Loans payable, net | 13,472 | - | ||||||||
| Leases, net of current portion | 5,879 | 6,309 | ||||||||
| Total liabilities | 28,860 | 15,495 | ||||||||
| Common stock | 165 | 165 | ||||||||
| Additional paid-in capital | 561,332 | 558,566 | ||||||||
| Subscription receivable | (23 | ) | - | |||||||
| Accumulated deficit | (525,472 | ) | (494,102 | ) | ||||||
| Accumulated other comprehensive income (loss) | (60 | ) | - | |||||||
| Total stockholders’ equity | 35,942 | 64,629 | ||||||||
| Total liabilities and stockholders’ equity | $ | 64,802 | $ | 80,124 | ||||||
FAQ
What were Trevena's financial results for Q2 2022?
What is the status of OLINVYK's clinical data?
What is the progress of TRV045 in clinical trials?
What cash reserves does Trevena have for operations?
What strategic agreements has Trevena entered into recently?
